Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026

manilatimes.net · 2026-10-13

Company Announcement

TickrTrends take: Genmab's DARZALEX net sales announcement for Q3 2026 provides concrete revenue data that investors should evaluate against TickrTrends' current overvalued assessment of the company. Since DARZALEX represents a significant portion of Genmab's revenue as a key multiple myeloma treatment, the magnitude of these sales figures will be essential for determining whether the current valuation appropriately reflects the drug's market performance and growth trajectory. Healthcare investors monitoring GMAB should compare the reported sales results to prior quarters and analyst expectations to assess whether the company's valuation premium is justified by its commercial execution.

Read the full story at manilatimes.net →